Luspatercept (post-transplant erythroid engraftment)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-03 — Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant: cross-connection with hyperbaric-oxygen-therapy-allo-hsct: Both address post-transplant hematologic recovery in MPN allo-HSCT — HBOT focused on neutrophil engraftment, luspatercept on erythroid recovery. (novelty: 4)
- 2026-04-20 — Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis: Prospective multicenter RCT planned to evaluate luspatercept (TGF-β superfamily modulator) for prevention of poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate-to-severe myelofibrosis (trial-early; design stage, no outcome data yet). (novelty: 4)
Open questions
Related
Contributing findings
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
20-apr-2026
novelty 4
per-area 4
introduces